Latest revenue
$0
as of 2025-09-30
Latest net income
$-683.0K
as of 2025-09-30
Net margin
—
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ATXI is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.4M
- Enterprise value
- $-1.0M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.76×
- Dividend yield
- 0.0%
- 52-wk high
- $0.97
- 52-wk low
- $0.15
- Beta
- —
- Shares out
- 3.3M
5-year trend
What this company does
Item 1. Business Overview Avenue Therapeutics, Inc. (“Avenue” or the “Company”) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. Our current product candidates are ATX-04, a selective β2-adrenergic agonist for Pompe disease, intravenous tramadol (“IV tramadol”), a schedule IV opioid for the treatment of post-operative acute pain and previously, through November 5, 2025, BAER-101 for the treatment of epilepsy and panic disorders. In February 2026, we announced the entry into an exclusive license agreement with Duke University for patents and know-how relating to clenbuterol (referred to as ATX-04), a…
AI summary unavailable — showing raw filing excerpt
Generated from ATXI's filing dated 2026-03-30
Key risks
Item 1A. Risk Factors Our business, financial condition, results of operations, and the industry in which we operate are subject to various risks. You should carefully consider the risks described below, in addition to the other information contained in this Form 10-K, before making an investment decision. The risks and uncertainties described below are not the only ones we face and you should not interpret the disclosure of a risk to imply that the risk has not already materialized. Additional risks not presently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations. Risks Pertaining to Our…
AI summary unavailable — showing raw filing excerpt
Generated from ATXI's filing dated 2026-03-30
Profitability
Operating margin
-219.6%
Net margin
-207.2%
Return on equity
-158.8%
61.9%Return on assets
-99.2%
77.2%Leverage
Debt / equity
0.60×
1442.3%Debt / assets
37.5%
901.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-695.0K | +62.5% | — |
Q4 2025 2025-12-31 | — | — | $-709.0K | +54.1% | — |
Q3 2025 2025-09-30 | $0 | — | $-683.0K | +77.8% | — |
Q2 2025 2025-06-30 | $1.4M | — | $335.0K | +112.4% | 23.9% |
Q1 2025 2025-03-31 | — | — | $-1.9M | +57.3% | — |
Q4 2024 2024-12-31 | — | — | $-1.5M | — | — |
Q3 2024 2024-09-30 | $0 | — | $-3.1M | -684.8% | — |
Q2 2024 2024-06-30 | $0 | — | $-2.7M | +32.8% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ATXI — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ATXI
Institutional value
$385.3K
Total shares held
192.6K
Distinct holders
8
As of
2024-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 140.0K | $280.0K | — | New |
| 2 | BOOTHBAY FUND MANAGEMENT, LLC | 41.1K | $82.2K | — | New |
| 3 | UBS Group AG | 7.9K | $15.8K | — | New |
| 4 | Tower Research Capital LLC (TRC) | 3.1K | $6.2K | — | New |
| 5 | WELLS FARGO & COMPANY/MN | 500 | $1.0K | — | New |
| 6 | BANK OF AMERICA CORP /DE/ | 14 | $28 | — | New |
| 7 | SBI Securities Co., Ltd. | 9 | $18 | — | New |
| 8 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ATXI's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.